Analysts on Wall Street project that Edwards Lifesciences (EW) will announce quarterly earnings of $0.62 per share in its forthcoming report, representing an increase of 5.1% year over year. Revenues are projected to reach $1.54 billion, increasing 11.1% from the same quarter last year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial e ...

Core Viewpoint - Elevance Health (ELV) is expected to report a quarterly earnings per share (EPS) of $3.07, reflecting a decline of 20.1% year-over-year, while revenues are forecasted to increase by 10.1% to $49.53 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower in the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Projections - Analysts predict 'Revenues- Service fees' at $2.13 billion, a year-over-year increase of 4.7% [5]. - 'Revenues- Premiums' are estimated at $40.69 billion, reflecting a 12.3% year-over-year increase [5]. - 'Revenues- Net investment income' is expected to reach $469.69 million, indicating a decline of 10.9% year-over-year [5]. - 'Revenues- Product revenue' is projected at $6.82 billion, a 1.5% year-over-year increase [6]. Membership Metrics - Total Medical Membership is projected to be 45.40 million, down from 45.73 million in the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is estimated at 2.24 million, up from 2.07 million year-over-year [7]. - 'Medical Membership - Medicaid' is expected to be 8.60 million, down from 8.92 million year-over-year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.63 million, slightly down from 1.66 million year-over-year [8]. - Total Medicare membership is expected to reach 3.11 million, up from 2.96 million year-over-year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is estimated at 1.33 million, up from 1.29 million year-over-year [9]. - 'Benefit Expense Ratio' is forecasted to be 93.4%, compared to 92.4% year-over-year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.08 million, down from 27.20 million year-over-year [9]. Stock Performance - Elevance Health shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [10]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [10].

Core Viewpoint - Analysts project that CSX will report quarterly earnings of $0.41 per share, reflecting a 2.4% decline year over year, with revenues expected to be $3.54 billion, indicating no change from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 3.9% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts forecast 'Revenue- Coal' to reach $481.51 million, a decrease of 3.5% year over year [5]. - 'Revenue- Intermodal' is expected to be $554.16 million, reflecting a year-over-year increase of 5.4% [5]. - 'Revenue- Merchandise- Fertilizers' is projected at $137.18 million, indicating a 9.7% increase year over year [5]. - 'Revenue- Merchandise- Chemicals' is estimated to be $698.20 million, showing a decline of 1.4% from the prior year [6]. Operating Metrics - The estimated 'Operating Margin' is projected to be 67.2%, significantly higher than the year-ago figure of 31.3% [6]. - 'Revenue per unit - Intermodal' is expected to be $707.85, slightly up from $705.00 in the same quarter last year [6]. Volume Estimates - 'Volume - Merchandise - Automotive' is expected to be 92.58 thousand, down from 96.00 thousand year over year [7]. - 'Volume - Merchandise - Minerals' is projected at 87.05 thousand, compared to 88.00 thousand last year [7]. - 'Volume - Coal' is estimated at 180.65 thousand, slightly up from 179.00 thousand in the previous year [7]. - 'Volume - Merchandise - Fertilizers' is expected to reach 47.64 thousand, an increase from 44.00 thousand year over year [8]. - 'Volume - Merchandise - Metals and Equipment' is projected at 63.03 thousand, consistent with last year's figure of 63.00 thousand [8]. - 'Volume - Merchandise - Agricultural and Food Products' is estimated at 115.31 thousand, down from 116.00 thousand year over year [9]. Stock Performance - CSX shares have returned -0.9% over the past month, contrasting with the Zacks S&P 500 composite's +2% change, and the company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance [9].

Core Insights - BlackRock (BLK) is expected to report quarterly earnings of $12.41 per share, a 4% increase year-over-year, with revenues projected at $6.75 billion, reflecting an 18.8% year-over-year growth [1] Earnings Projections - The consensus EPS estimate has been revised upward by 1.6% over the past 30 days, indicating analysts have reassessed their projections [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Analysts predict 'Revenue- Technology services revenue' to be $528.86 million, a year-over-year increase of 23.6% [5] - 'Revenue- Investment advisory, administration fees and securities lending revenue- Equity subtotal' is estimated to reach $2.28 billion, reflecting a 6.5% increase from the previous year [5] - The total investment advisory, administration fees, and securities lending revenue is forecasted at $5.30 billion, indicating a 19.9% year-over-year growth [6] - 'Revenue- Distribution fees' is expected to be $371.59 million, a 15.4% increase year-over-year [6] Net Inflows - The consensus for 'Net inflows' is projected at $232.59 billion, down from $281.42 billion year-over-year [7] - 'Net inflows - Product Type - Cash management' is expected to be $38.38 billion, compared to $80.75 billion from the previous year [7] - 'Net inflows - Client Type - ETFs' is estimated at $124.04 billion, down from $142.64 billion year-over-year [9] - 'Net inflows - Product Type - Long-term' is projected to reach $168.83 billion, compared to $200.67 billion from the previous year [10] Assets Under Management - 'Assets under management - Cash management' is estimated at $1,059.97 billion, up from $920.66 billion year-over-year [8] - Total Assets Under Management is projected to be $13,989.59 billion, compared to $11,551.25 billion in the same quarter of the previous year [8] - 'Assets under management - Long-term' is expected to be $12,949.98 billion, up from $10,630.59 billion year-over-year [9] - 'Assets under management - ETFs' is projected to reach $5,355.98 billion, compared to $4,230.38 billion from the previous year [10] Stock Performance - BlackRock shares have changed by -0.4% in the past month, contrasting with a +1.9% move of the Zacks S&P 500 composite [11] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance in the near future [11]

Wall Street analysts forecast that Morgan Stanley (MS) will report quarterly earnings of $2.43 per share in its upcoming release, pointing to a year-over-year increase of 9.5%. It is anticipated that revenues will amount to $17.32 billion, exhibiting an increase of 6.8% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 5.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassesse ...

Financial Projections - Myriad Genetics, Inc. expects fourth quarter total revenues to be between $207 million and $209 million [1] - For the full year 2025, total revenues are projected to be between $822 million and $824 million [1] - For the full year 2026, the company projects revenue in a range of $860 million to $880 million and adjusted EBITDA in a range of $37 million to $49 million [1] Earnings Call - The company plans to release its actual financial results for the fourth quarter during its earnings call scheduled for February 2026 [1]

Group 1 - Allstate's stock closed at $204.93, down 1.98%, underperforming the S&P 500's gain of 0.79% [1] - Over the past month, Allstate shares have decreased by 0.4%, while the Finance sector and S&P 500 have increased by 4.09% and 0.87%, respectively [1] Group 2 - The upcoming earnings per share (EPS) for Allstate is projected at $8.05, reflecting a 4.95% increase year-over-year, with revenue expected to reach $17.63 billion, a 5.53% increase from the same quarter last year [2] - For the entire fiscal year, earnings are projected at $28.21 per share and revenue at $68.95 billion, indicating increases of 53.98% and 7.19% from the previous year [3] Group 3 - Recent revisions to analyst forecasts for Allstate are crucial as they indicate changing business trends, with positive revisions suggesting a favorable outlook on the company's health and profitability [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Allstate as 1 (Strong Buy), with a historical average annual return of +25% for 1 stocks since 1988 [6] Group 4 - Allstate's Forward P/E ratio is 7.41, indicating a discount compared to the industry's Forward P/E of 11.66, while its PEG ratio stands at 0.39, significantly lower than the industry average of 1.63 [7] - The Insurance - Property and Casualty industry, part of the Finance sector, ranks 27 in the Zacks Industry Rank, placing it in the top 11% of over 250 industries [8]

Company Performance - Symbotic Inc. (SYM) experienced a decline of 3.44% in its stock price, closing at $61.43, while the S&P 500 fell by 1.07% [1] - Over the past month, SYM shares have appreciated by 6.89%, outperforming the Business Services sector's gain of 2.99% and the S&P 500's gain of 0.94% [1] Upcoming Earnings - The upcoming earnings release is projected to show earnings of $0.09 per share, indicating a year-over-year growth of 400% [2] - The Zacks Consensus Estimate for revenue is $622.31 million, reflecting a 27.86% increase from the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of $0.42 per share and revenue of $2.72 billion, representing changes of -76.92% and +21.1% respectively from last year [3] Analyst Estimates - Recent adjustments to analyst estimates for Symbotic Inc. are important as they reflect short-term business trends [4] - Upward revisions in estimates indicate analysts' positive outlook on the company's operations and profit generation capabilities [4] Zacks Rank and Valuation - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently ranks Symbotic Inc. at 4 (Sell) [6] - The Forward P/E ratio for SYM is 153.3, significantly higher than the industry average of 19.54, suggesting that SYM is trading at a premium [7] - SYM has a PEG ratio of 5.11, compared to the industry average PEG ratio of 1.82 [7] Industry Context - The Technology Services industry, part of the Business Services sector, holds a Zacks Industry Rank of 85, placing it in the top 35% of over 250 industries [8] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [8]

Core Insights - Analysts project Oracle (ORCL) will report quarterly earnings of $1.63 per share, reflecting a 10.9% year-over-year increase, with revenues expected to reach $16.15 billion, a 14.8% increase from the same quarter last year [1] Revenue Estimates - The consensus estimate for 'Revenue- Hardware' is $713.60 million, indicating a year-over-year change of -2% [4] - The estimate for 'Revenue- Services' stands at $1.36 billion, reflecting a year-over-year change of +2% [4] - 'Cloud Services and License Support Revenues by Ecosystem- Applications cloud services and license support' is projected to be $3.87 billion, showing a year-over-year decline of -19.1% [4] - 'Cloud Services and License Support Revenues by Ecosystem- Infrastructure cloud services and license support' is expected to be $4.16 billion, indicating a -30.9% change from the prior-year quarter [5] Geographic Revenue Estimates - 'Geographic Revenue- Americas' is estimated to be $10.23 billion, reflecting a year-over-year increase of +14.6% [5] - 'Geographic Revenue- Asia-Pacific' is projected at $1.92 billion, indicating a year-over-year change of +10.2% [6] - 'Geographic Revenue- Europe, Middle East and Africa' is expected to reach $3.98 billion, reflecting a +17.6% change from the prior-year quarter [6] Stock Performance - Oracle shares have decreased by -12.1% over the past month, contrasting with the Zacks S&P 500 composite's increase of +1.3% [6] - Oracle holds a Zacks Rank of 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6]

Core Viewpoint - Central Garden & Pet Company is set to release its quarterly earnings on November 24, 2025, with analysts predicting an EPS of -$0.20 and revenue of approximately $657.86 million for the quarter [1][6]. Financial Projections - Analysts anticipate a year-over-year decline in earnings and lower revenues, but Zacks Investment Research suggests the company may exceed these estimates, which could positively affect the stock price [2]. - A miss on earnings expectations could lead to a decrease in stock value, making the management's discussion during the earnings call critical for assessing immediate price changes [2]. Financial Metrics - The company has a price-to-earnings (P/E) ratio of 13.98, indicating the amount investors are willing to pay per dollar of earnings [3][6]. - The price-to-sales ratio is 0.61, reflecting the market's valuation of its sales [3][6]. - The enterprise value to sales ratio stands at 0.85, showing the company's total valuation relative to its sales [3]. - The enterprise value to operating cash flow ratio is 7.48, suggesting how the company's cash flow is valued in relation to its enterprise value [4]. - Central Garden has an earnings yield of 7.15%, indicating a return on investment relative to its share price [4]. - The debt-to-equity ratio is 0.90, showing the proportion of debt used to finance the company's assets relative to shareholders' equity [4]. - The current ratio is 3.56, indicating a strong ability to cover short-term liabilities with short-term assets, which is crucial given the challenges of declining earnings and revenue projections [5].